Carisma Therapeutics Inc. Revenue
Carisma Therapeutics Inc. reported Revenue of $45.30 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-12
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $45.30M, a 1232.35% increase year-over-year.
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $3.70M, a 8.82% increase year-over-year.
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $3.60M, a 16.28% decline year-over-year.
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $19.60M, a 31.54% increase from fiscal 2023.
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $14.90M, a 52.04% increase from fiscal 2022.
- Carisma Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $9.80M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $45.30M 10-Q · filed 2025-11-12 | $45.30M derived: sum of 2 quarters · filed 2025-11-12 | $49.00M 10-Q · filed 2025-11-12 | $52.60M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.70M 10-Q · filed 2025-08-07 | $7.30M derived: sum of 3 quarters · filed 2025-08-07 | $10.70M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2025-03-31 | $3.70M 10-Q · filed 2025-05-13 | $7.30M derived: sum of 2 quarters · filed 2025-05-13 | $10.70M derived: sum of 3 quarters · filed 2025-11-12 | $19.90M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.00M derived: sum of 2 quarters · filed 2025-11-12 | $16.20M derived: sum of 3 quarters · filed 2025-11-12 | $19.60M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $3.40M 10-Q · filed 2025-11-12 | $12.60M derived: sum of 2 quarters · filed 2025-11-12 | $16.00M 10-Q · filed 2025-11-12 | $20.30M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $9.20M 10-Q · filed 2024-08-08 | $12.60M 10-Q · filed 2025-08-07 | $16.90M derived: sum of 3 quarters · filed 2025-05-13 | $20.70M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2024-03-31 | $3.40M 10-Q · filed 2025-05-13 | $7.70M derived: sum of 2 quarters · filed 2025-05-13 | $11.50M derived: sum of 3 quarters · filed 2025-05-13 | $15.10M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $8.10M derived: sum of 2 quarters · filed 2025-03-31 | $11.70M derived: sum of 3 quarters · filed 2025-03-31 | $14.90M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $3.80M 10-Q · filed 2024-11-07 | $3.83M 10-Q · filed 2023-11-09 | $7.40M derived: sum of 2 quarters · filed 2024-11-07 | $10.60M 10-Q · filed 2024-11-07 | $10.63M 10-Q · filed 2023-11-09 | $14.30M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.60M 10-Q · filed 2024-08-08 | $3.56M 10-Q · filed 2023-08-10 | $6.80M 10-Q · filed 2024-08-08 | $6.80M 10-Q · filed 2023-08-10 | $10.50M derived: sum of 3 quarters · filed 2024-08-08 | $13.07M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $3.20M 10-Q · filed 2024-05-09 | $3.24M 10-Q · filed 2023-05-11 | $6.90M derived: sum of 2 quarters · filed 2024-05-09 | $9.47M derived: sum of 3 quarters · filed 2024-05-09 | $12.18M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $6.28M derived: sum of 2 quarters · filed 2024-04-01 | $8.98M derived: sum of 3 quarters · filed 2024-04-01 | $9.80M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $2.58M 10-Q · filed 2023-11-09 | $5.28M derived: sum of 2 quarters · filed 2023-11-09 | $6.10M 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | $2.70M 10-Q · filed 2023-08-10 | $3.52M 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $822.00K 10-Q · filed 2023-05-11 |